Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT00071422. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Rising-dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Insulin-using Type 2 Diabetes Mellitus Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.
Study identification
- NCT ID
- NCT00071422
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 126 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 35 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2003 (Type not available)
- Primary completion
- Jun 2004 (Actual)
- Completion
- Jun 2004 (Actual)
- Last update posted
- Jul 11, 2014
2003 – 2004
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Diabetes and Endocrine Associates | La Jolla | California | 92037 | — |
| VA Hospital UCSD | San Diego | California | 92161 | — |
| Diablo Clinical Research | Walnut Creek | California | 94598 | — |
| Not listed | Denver | Colorado | 80209 | — |
| Longmont Medical Research Network | Longmont | Colorado | 80501 | — |
| MedStar Clinical Research Center | Washington D.C. | District of Columbia | 20003 | — |
| Future Care Studies | Springfield | Massachusetts | 01107 | — |
| Mercury Street Medical | Butte | Montana | 59701 | — |
| Diabetes-Endocrinology Center of WNY | Buffalo | New York | 14209 | — |
| UNC Diabetes Care Center | Durham | North Carolina | 27713 | — |
| Piedmont Medical Group | Winston-Salem | North Carolina | 27103 | — |
| Clinical Research Institute of Southern Oregon | Medford | Oregon | 97504 | — |
| Mountain View Clinical Research | Greer | South Carolina | 29651 | — |
| Dallas Diabetes and Endocrine Center | Dallas | Texas | 75230 | — |
| University of Texas Health Science Center - Texas Diabetes Institute | San Antonio | Texas | 78207 | — |
| DGD Research Associates | San Antonio | Texas | 78229 | — |
| Charlottesville Medical Research | Charlottesville | Virginia | 22911 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00071422, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2014 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00071422 live on ClinicalTrials.gov.